Loading…
Lobbying Income
$94K
Filings
17
Unique Clients
2
Active Period
2016–2023
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
WHO Withdrawal Act
2023 · third_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Monitoring and discussing House and Senate legislation related to the WHO Pandemic Prevention and Response Accord, specifically the WHO Withdrawal Act H.R. 79 and No WHO Pandemic Treat Without Senate Approval Act S. 444.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 79
No WHO Pandemic Preparedness Treaty Without Senate Approval Act
2023 · third_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Monitoring and discussing House and Senate legislation related to the WHO Pandemic Prevention and Response Accord, specifically the WHO Withdrawal Act H.R. 79 and No WHO Pandemic Treat Without Senate Approval Act S. 444.
Client expense: — · Firm income: $10,000
Matched citations: S. 444
To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.
2022 · fourth_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: H.R.5214
Dietary Supplement Listing Act of 2022
2022 · fourth_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: S. 4090
FDASLA Act of 2022
2022 · fourth_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: S 4348
American Technology Leadership Act of 2022
2022 · fourth_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: S. 4368
To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.
2022 · third_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Consideration of a Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: H.R.5214
Dietary Supplement Listing Act of 2022
2022 · third_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Consideration of a Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: S. 4090
FDASLA Act of 2022
2022 · third_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Consideration of a Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: S 4348
American Technology Leadership Act of 2022
2022 · third_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Consideration of a Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: S. 4368
To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.
2022 · second_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Consideration of a Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: H.R.5214
Dietary Supplement Listing Act of 2022
2022 · second_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Consideration of a Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: S. 4090
FDASLA Act of 2022
2022 · second_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Consideration of a Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: S 4348
American Technology Leadership Act of 2022
2022 · second_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Consideration of a Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA: S. 4090 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA. 4) S 4348 - FDA User Free Reauthorization Package (S. 4368) - did not support additional amendments added affecting the supplement industry
Client expense: — · Firm income: $10,000
Matched citations: S. 4368
To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.
2022 · first_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Consideration of a Mandatory Product Listing for the Dietary Supplement Industry, to be housed at the FDA. No current legislation or bill #. 3) For the natural substance known as N-Acetyl-L-Cysteine (NAC) to remain legal as a dietary supplement by the FDA.
Client expense: — · Firm income: $10,000
Matched citations: H.R.5214
To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.
2021 · fourth_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Support for Mandatory Product Listing for the Dietary Supplement Industry, both voluntarily and for consideration of the listing to be supported by the FDA.
Client expense: — · Firm income: $9,000
Matched citations: H.R.5214
To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.
2021 · third_quarter · Client: ORTHO MOLECULAR PRODUCTS, INC.
Issues concerning the dietary supplement industry, including 1) support for H.R.5214 (and eventual Senate Companion) - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements. 2) Support for Mandatory Product Listing for the Dietary Supplement Industry, both voluntarily and for consideration of the listing to be supported by the FDA.
Client expense: — · Firm income: —
Matched citations: H.R.5214
Source: Senate LDA